Sabine Tejpar, MD, PhD
Dr. Sabine Tejpar received her medical degree from the Catholic University Leuven (K.U. Leuven, Belgium) in 1995 and did her residency in the Department of Internal Medicine, Division of Gastroenterology, at the University Hospital Gasthuisberg, Leuven. In 2000, she obtained her Ph.D from the program in Molecular Oncology at the Center for Human Genetics at K. U. Leuven. After her medical and scientific training, she joined UZ Leuven as an Associate Professor in the Department of Gastroenterology, Digestive Oncology Unit. She is currently an Associate Professor of Medicine at the K.U. Leuven as well as a Senior Clinical Investigator of the Fund for Scientific Research in Flanders, Belgium where her research focuses on the molecular sub-classification of colorectal cancer, prognostic markers in adjuvant colorectal cancer, and predictive markers for efficacy of EGFR inhibition. She is also a practicing clinician serving at Adjunct Clinical Head of the Department of Gastroenterology, Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven. Dr. Tejpar is an active member of the European Organization for Research and Treatment of Cancer (EORTC) where she also serves as vice-chair of the EORTC translational research advisory committee, board member of the Gastrointestinal Group, member of the EORTC Network of Core Institutions (NOCI) steering committee and executive committee, member of the EORTC Pharmacology and Molecular Mechanisms Group and Laboratory Research Division, co-chair of the EORTC-NCI-ASCO tutorial, and member of the AACR-NCI-EORTC program committee. She is also on the American Society of Clinical Oncology (ASCO) program committee, a member of the Belgian Group for Digestive Oncology (BGDO), and a board member of the Belgian Familial Adenomatous Polyposis Assocation (FAPA). Since 2009, Dr. Tejpar has also been a member of the European Society of Medical Oncology (ESMO) translational research working group and since 2006 a member of the Ministerial advisory committee for colon cancer prevention in Flanders.